Abstract
Even though HD is not an AIDS defining disease, the
relative risk (RR) for developing HD is definitively higher in at least
some of the subgroups of patients with HIV infecction (HIVpos).
Once it became evident that there was a clinical entity with overall
features distinct from HD, one sought to establish HD-HIV epidemiological
profile; to determine if there was a specific subgroup at higher risk
for the development of this new entity or a subgroup in which it did
not occur; to define the biological tumor profile; and the chance that
these changes to influence the clinical features, the profile of therapeutic
responses, and disease-free survival.
As HIVpos patients present a more aggressive Hodgkin Disease and immunological
changes that compromise the therapeutic response seen in the general
population, the treatment strategy has shifted, in order to reach complete
remission (CR) rates and longer survival time with the use of highly
effective antiretroviral schemes, adjustments of old chemotherapy schemes,
and new therapeutic protocols.
This article presents and analyses the factors involved in HD-HIV pathogenesis
and therapeutics.
Key words: Hodgkin's Disease; HIV; EBV; epidemiology;
pathology; therapy.
